Report: AstraZeneca Weighs Roughly $10B Bid for Rhythm Pharmaceuticals
- The Wall Street Journal, citing anonymous sources, reported that AstraZeneca offered about $10 billion, or $124 per share, for Rhythm; the deal is unconfirmed.
- BioSpace found no comment from either company, and Rhythm shares closed up 24% on Wednesday.
- Rhythm's MC4R drug Imcivree brought in $92.1 million in third-quarter sales and gained a hypothalamic obesity approval in March.
💡 Points Based on public reports
If accurate, this is AstraZeneca paying for a commercial rare-disease franchise rather than a pipeline option: Imcivree's $92.1 million quarter is modest against a $10 billion price, so the premium is really for MC4R biology and the hypothalamic obesity label. I'd read it as a hedge against crowded incretin obesity, buying a differentiated, orphan-protected niche. Rival bidders would likely prize the same scarcity.
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca ↗